| Patents for A61P 27 - Drugs for disorders of the senses (53,017) |
|---|
| 04/17/2003 | WO2003030913A2 Use of dendrimers in an ophthalmic composition |
| 04/17/2003 | WO2003030906A1 Treating infections by administration of oxazolidinones to the skin |
| 04/17/2003 | WO2003030897A1 Pyrrolidinone derivatives |
| 04/17/2003 | WO2003030894A1 Methods for treating dry eye |
| 04/17/2003 | WO2003030893A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| 04/17/2003 | WO2003030892A1 Methods for treating dry eye |
| 04/17/2003 | WO2003030876A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | WO2003030833A2 Angiopoietin-2 specific binding agents |
| 04/17/2003 | WO2003014315A3 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 04/17/2003 | WO2003008457A3 Polysaccharidic esters of retinoic acid |
| 04/17/2003 | WO2003005999A3 Methods of treating cytokine mediated diseases |
| 04/17/2003 | WO2002085930A3 Immunomodulating agents from parasitic worms and method for isolation thereof |
| 04/17/2003 | WO2002085928A3 Modified cyclosporine which can be used as a pro-drug and use thereof |
| 04/17/2003 | WO2002083700A3 Hypersulfated disaccharides and methods of using the same for the treatment of inflammations |
| 04/17/2003 | WO2002079221A3 Sapogenin derivatives, their synthesis and use |
| 04/17/2003 | WO2002076486A3 Histidine-rich glycoprotein |
| 04/17/2003 | WO2002072105A3 Improved prostanoid therapies for the treatment of glaucoma |
| 04/17/2003 | WO2002050289A9 Methods for the production of multimeric proteins, and related compositions |
| 04/17/2003 | WO2002047704A9 Herbal pharmaceutical compositions for treating immunological disorders |
| 04/17/2003 | WO2002032865A1 Novel neurokinin antagonists, method for the production thereof and pharmaceutical compositions containing said compounds |
| 04/17/2003 | WO2002029036A3 Lipid metabolism enzymes |
| 04/17/2003 | WO2002020619A9 HUMAN ANTIBODIES AGAINST PSEUDOMONAS AERUGINOSA LPS DERIVED FROM TRANSGENIC XENOMOUSE$m(3) |
| 04/17/2003 | WO2002018445A3 Co-crystal structure of monoclonal antibody 5c8 and cd154, and use thereof in drug design |
| 04/17/2003 | WO1999064401A3 Imidazolyl derivatives and their use as somatostatin receptor ligands |
| 04/17/2003 | US20030073849 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 04/17/2003 | US20030073846 Aminoalcohol derivatives |
| 04/17/2003 | US20030073845 Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors |
| 04/17/2003 | US20030073825 Azalide antibiotic compositions |
| 04/17/2003 | US20030073727 Central nervous system disorders |
| 04/17/2003 | US20030073720 Tryptase inhibitors |
| 04/17/2003 | US20030073718 Enzyme inhibitors; cardiovascular disorders; antiinflammatory agents; autoimmune disease |
| 04/17/2003 | US20030073712 Antiinflamamtory agents; antiischemic agents |
| 04/17/2003 | US20030073707 Quinuclidine-substituted hetero-bicyclic aromatic compounds for the treatment of disease |
| 04/17/2003 | US20030073699 Compounds and methods to treat cardiac failure and other disorders |
| 04/17/2003 | US20030073694 Topical applying to eyes; side effect reduction |
| 04/17/2003 | US20030073685 Nitric oxide synthase inhibitor; antiinflammatory agents |
| 04/17/2003 | US20030073682 Novel substituted aryl hydroxamic acids as metalloproteinase inhibitors |
| 04/17/2003 | US20030073676 Dissolving in aqueous carrier; antiallergens |
| 04/17/2003 | US20030073167 DNA encoding SNORF36 receptors |
| 04/17/2003 | US20030073123 Detection of modulators of gene transcription inhibition; obtain sample of cells, incubate with modulator, monitor transcription pattern, compare to control, evaluate for transcription inhibition |
| 04/17/2003 | US20030073076 Analyzing modulators or treatments of fibroproliferative diseases; obtain sample, incubate with modulator, monitor marker expression, decreased expression indicate effective modulator |
| 04/17/2003 | US20030072824 Having anti-oxidant, gastric mucosa injury inhibiting, aldose reductase inhibiting, blood glucose level elevation inhibiting action, platelet agglutination accelerating action, alcohol absorption inhibition, anti-inflammation properties |
| 04/17/2003 | US20030072822 Methods for treating disorders using plant extracts |
| 04/17/2003 | US20030072737 Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs |
| 04/17/2003 | CA2463364A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | CA2463339A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | CA2463198A1 Pyrrolidinone derivatives |
| 04/17/2003 | CA2462892A1 Human 3 relaxin |
| 04/17/2003 | CA2462881A1 Intraorally disintegrating valdecoxib compositions prepared by spray drying process |
| 04/17/2003 | CA2462862A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | CA2462272A1 Methods for treating dry eye by a combination of an antiinflammatory steroid and a muc-1 secretagogue |
| 04/17/2003 | CA2461435A1 Angiopoietin-2 specific binding agents |
| 04/17/2003 | CA2460476A1 Protein modification and maintenance molecules |
| 04/16/2003 | EP1302458A1 Ester derivatives |
| 04/16/2003 | EP1301598A2 Cell cycle proteins and mitosis-associated molecules |
| 04/16/2003 | EP1301595A2 G-protein coupled receptors |
| 04/16/2003 | EP1301535A2 G-protein coupled receptors |
| 04/16/2003 | EP1301524A1 B7-like polynucleotides, polypeptides, and antibodies |
| 04/16/2003 | EP1301522A1 Novel compounds and methods |
| 04/16/2003 | EP1301514A1 Aryl and heteroaryl diazabicycloalkanes, their preparation and use |
| 04/16/2003 | EP1301500A1 Nitrosated and nitrosylated taxanes, compositions and methods of use |
| 04/16/2003 | EP1301497A1 Colchinol derivatives as vascular damaging agents |
| 04/16/2003 | EP1301484A2 Capsaicin receptor ligands |
| 04/16/2003 | EP1301482A1 Cyclic amine phenyl beta-3 adrenergic receptor agonists |
| 04/16/2003 | EP1301476A1 New combination of serotonin agonist (5ht2) and antagonist (5ht6)as pharmaceutical formulation |
| 04/16/2003 | EP1301210A2 Compositions containing therapeutically active components having enhanced solubility |
| 04/16/2003 | EP1301203A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 04/16/2003 | EP1181017B1 Metalloprotease inhibitors |
| 04/16/2003 | EP1007505B1 Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives |
| 04/16/2003 | EP0977565B1 Pharmaceutical composition comprising a tricyclic compound with enhanced stability, absorbability and low irritation potential |
| 04/16/2003 | EP0869945B1 Catechol diethers derivatives useful as pharmaceutical agents |
| 04/16/2003 | EP0824544B1 Peptidyl compounds which inhibit metalloproteinase and tnf liberation and their therapeutic use |
| 04/16/2003 | CN1411458A Saccharin derivatives as orally active elastase inhibitors |
| 04/16/2003 | CN1411447A Polymorphic crystalline forms of celecoxib |
| 04/16/2003 | CN1411446A Ortho-sulfonamido aryl hydroxamic acids, process for their preparation and their use as matrix metalloproteinase inhibitors |
| 04/16/2003 | CN1411444A Vitronectin receptor antagonist bicyclic compounds, preparation method and compositions containing same |
| 04/16/2003 | CN1411440A Pharmaceutical compositions containing 3-amino-azetidine derivatives, novel derivatives and preparation thereof |
| 04/16/2003 | CN1410071A Archimycin gel for eye application |
| 04/16/2003 | CN1105723C Spirocyclic metalloprotease inhibitors |
| 04/16/2003 | CN1105576C Insulin analog formulation |
| 04/16/2003 | CN1105574C Therapeutic uses of bactericidal/permeability increasing protein products |
| 04/15/2003 | US6548671 Quinoxalinyl amide derivatives |
| 04/15/2003 | US6548667 For prevention and treatment of diseases caused by overexpression and overactivation of matrix metalloproteinase |
| 04/15/2003 | US6548638 Peptoid and nonpeptoid containing α-keto oxadiazoles as serine protease inhibitors |
| 04/15/2003 | US6548542 Vision through photodynamic therapy of the eye |
| 04/15/2003 | US6548520 Substituted imidazoles having anti-cancer and cytokine inhibitory activity |
| 04/15/2003 | US6548503 Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines |
| 04/15/2003 | US6548500 Treating a cell adhesion-mediated diseases such as multiple sclerosis, asthma, atherosclerosis, rheumatoid arthritis, meningitis, comprising administering to a warm blooded animal a nitrogen atoms containing bicyclic compound |
| 04/15/2003 | US6548497 Methods of reducing non-inflammatory pain |
| 04/15/2003 | US6548475 Use of the KAL protein and treatment with the KAL protein in treatment of retinal, renal, neuronal and neural injury |
| 04/15/2003 | US6548078 Implanting a sustained release device to deliver the corticosteroid to the vitreous of the eye and wherein aqueous corticosteroid concentration is less than vitreous corticosteroid concentration during release |
| 04/15/2003 | CA2190485C Lacrimal gland specific emulsions for topical application to ocular tissue |
| 04/15/2003 | CA2070573C Derivatives of amide analogs of certain methano bridged quinolizines |
| 04/15/2003 | CA2053208C Hydroxyalkylquinoline ether acids as leukotriene antagonists |
| 04/11/2003 | WO2002030934A1 Substituted 3.4-dihydro-pyrimido[1,2-a]pyrimidines and 3.4-dihydropyrazino[1,2-a]pyrimidines |
| 04/11/2003 | WO2002030872A1 Novel aliphatic compounds, process for their preparation and their usage |
| 04/11/2003 | CA2425923A1 Novel aliphatic compounds, process for their preparation and their usage |
| 04/11/2003 | CA2425685A1 Substituted 3.4-dihydro-pyrimido[1,2-a]pyrimidines and 3.4-dihydropyrazino[1,2-a]pyrimidines |
| 04/10/2003 | WO2003029293A2 Modulators of notch ic protease activity for use in immunotherapy |
| 04/10/2003 | WO2003029252A1 Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease |